Menu
delpharm

PrEsentation

Pharmaceutical Contract Manufacturing Organisation (CMO)

Management

Xavier Castelli, CEO
Sébastien Aguettant, Managing Director
Laurent Gareau, Finance Director

Investment date

April 2004
June 2007

Investment Type

MBO, spin-off (Laboratoire Aguettant), build-up

Activa Capital's role

Majority shareholder

Turnover 2007

€94M

Location

Tours, Brétigny-sur-Orge, Evreux, Lille - 550 employees

Project

Reinforce Delpharm's leading position in the French market through the acquisition of other CMOs in France and Europe.

Build-up

In May 2006, Delpharm acquired from Schering its French manufacturing plant based in Lille. In 2005, this unit realised sales of €36m.

Exit

In June 2007, Activa Capital exited Delpharm. The management team has acquired a majority stake in Delpharm.

www.delpharm.com

< back

delpharm

PrEsentation

Pharmaceutical Contract Manufacturing Organisation (CMO)

Management

Xavier Castelli, CEO
Sébastien Aguettant, Managing Director
Laurent Gareau, Finance Director

Investment date

April 2004
June 2007

Investment Type

MBO, spin-off (Laboratoire Aguettant), build-up

Activa Capital's role

Majority shareholder

Turnover 2007

€94M

Location

Tours, Brétigny-sur-Orge, Evreux, Lille - 550 employees

1 boulevard de la Madeleine - F-75001 Paris
Tél. +33 1 43 12 50 12 - Fax +33 1 43 12 50 13
S.A.S au capital de 487 836,84 € - RCS Paris B 428 998 710 - Siret 428 998 710 00035 - APE 6430Z

We support - United Nations Global Impact iC20 Principles for Responsable Investment ^